Uppsala, Sweden, 2013-03-01 08:49 CET (GLOBE NEWSWIRE) --
THIRD QUARTER November 1, 2012 – January 31, 2013
- Consolidated Net sales amounted to € 0 thousand (0)[1]
- Operating income amounted to € -1,670 thousand (-2,014)
- Net income after tax amounted to € -1,802 thousand (-1,999)
- Earnings per share amounted to € -0.02 (-0.03)
- Comprehensive income amounted to € -1,802 thousand (-1,999)
- Oasmia and Abbott enter into a global collaboration agreement for the veterinary oncology market
- Nexttobe increases its ownership in Oasmia
- Preferential rights new share issue completed
THE PERIOD May 1, 2012 – January 31, 2013
- Consolidated Net sales amounted to € 0 thousand (103)
- Operating income amounted to € -5,296 thousand (-5,349)
- Net income after tax amounted to € -5,733 thousand (-5,327)
- Earnings per share amounted to € -0.09 (-0.10)
- Comprehensive income amounted to € -5,733 thousand (-5,327)
EVENTS AFTER CLOSING DAY
- Oasmia and Pharmasyntez enter into a distribution agreement for Paclical® in Russia and CIS
[1] The numbers in parentheses concern results from the corresponding period of the previous year
Johan Edin, acting Head of PR & Communications +46 18 50 54 40, press@oasmia.com, twitter.com/oasmia
